%20(1).png)
Cancer DNA Risk Prediction / Hereditary Cancer Genetic Test & ctDNA Screening
Assessment Scope: Germline Hereditary Variant Next-Generation Sequencing & Somatic Circulating Tumor DNA Liquid Biopsy Screening
Objective: Combining innate germline susceptibility and acquired sub-clinical oncological dynamic biomarkers to bypass the structural limitations of conventional imaging, establishing a dual-barrier precision framework for predictive prevention and hyper-early cancer interception.
I. Rationale for Personalized Supplementation & Assessment
Clinical Core: Carcinogenesis is the clinical endpoint of long-term synergy between innate germline susceptibility and acquired cellular damage driven by oxidative stress, chronic inflammation, and environmental toxicants. Standard imaging modalities (such as LDCT, ultrasound, or colonoscopy) are structural diagnostics; they fail to register lesions until a tumor mass measures at least 0.5 to 1 cm, a stage already comprising hundreds of millions of malignant cells. This molecular genomic profiling establishes a dual-barrier clinical firewall. First, it identifies **germline variant mutations** (e.g., BRCA1/2) to calculate lifelong oncological risk, redirecting functional lifestyles away from epigenetic triggers. Second, utilizing ultra-sensitive **liquid biopsy (ctDNA) sequencing**, it detects minute fragments of tumor DNA shed into peripheral blood by dying malignant cells years before structural nodules manifest on conventional scans.
1. Germline Susceptibility Profiling: Deciphering Hereditary Oncological Codes: Approximately 5% to 10% of malignancies possess a definitive hereditary genetic etiology (such as HBOC or Lynch Syndrome). Screening for germline variants maps whether an individual possesses inherited genetic bottlenecks. This doesn't serve to induce medical anxiety, but rather allows clinicians to build highly customiz-ed chemoprevention strategies (e.g., up-regulating hepatic Phase conjugation or aggre-ssively chelating environmental toxic burdens).
2. Acquired ctDNA Liquid Biopsy: Piercing Imaging Blind Spots for Pre-Clinical Interception: As microscopic aberrant cells proliferate and undergo apoptosis under immune evasion, they shed highly specific fragments known as circulating tumor DNA (ctDNA) into the blood. Liquid biopsy sequencing isolates these molecules harboring tumor-specific somatic mutations or epigenetic methylation tags at parts-per-million sensitivity. Clinical trials demonstrate that ctDNA spikes alert clinicians to early neoplastic activity months or years prior to radiographic validation.
3. Directing Precision Functional Interventions and Epigenetic Tailoring: Genetics designs the blueprint, but epigenetics determines gene expression. If an individual exhibits downregulated tumor suppressor gene efficiency (e.g., TP53 pathways) or glutathione S-transferase deletions (GSTM1), clinicians can counter this by enriching daily bespoke nutrient packs with targeted sulforaphane, resveratrol, highbioavailability curcumin, or active methyl donors (5-MTHF) to enhance DNA repair mechanics and bolster antiinflammatory defenses.
II. Comprehensively Evaluated Biomarkers
English Translation
1. Innate Germline Cancer Susceptibility Panel (Next-Gen Sequencing)
Tumor Suppressor & DNA Repair Variants: Decodes high-penetrance genes including BRCA1 / BRCA2 (breast, ovarian, prostatic, and pancreatic risks), TP53 (Li-Fraumeni syndrome), PTEN, APC (familial adenomatous polyposis), and other critical loci.
Mismatch Repair (MMR) Genes: MLH1, MSH2, MSH6, and PMS2. Evaluates presence of Lynch Syndrome, intrinsically tied to hereditary colorectal and endometrial malignancies.
2. Acquired Circulating Tumor DNA Somatic Variants (ctDNA Liquid Biopsy) Hotspot Oncogenic Driver Mutations: Utilizes ultra-deep genomic sequencing to capture lowfrequency cell-free somatic variants, including EGFR, KRAS, NRAS, BRAF, and PIK3CA, signaling whether sub-clinical malignant clones are actively mutating or expanding.
3. ctDNA Methylation Signatures & Tissue-of-Origin (TOO) Tracing
Epigenetic Aberrant Methylation Fingerprints: Early-stage neoplastic cell lines display hyperspecific DNA methylation alterations. This scan interprets cell-free DNA (cfDNA) profiles for these aberrant epigenetic signatures.
Tissue-of-Origin (TOO) Mapping: If an early-stage sub-clinical trace is isolated, machine-learning algorithms cross-reference the methylation tags to map its source organ (e.g., lungs, liver, colorectum, stomach, or pancreas), streamlining focused clinical radiographic tracking.
4. Systemic Onco-Immunological Microenvironment & Epigenetic Load Microsatellite Instability (MSI Status): Screens cell-free DNA fragments to check for global genomic instability and mismatch repair deficits.
Inflammatory Pathway Overload: Assesses whether the systemic biochemical terrain is chronically inflamed—providing fertile soil for malignant transformation. This interacts with your Organic Acids (OAT) and Hormonal (DUTCH) diagnostics to construct a definitive preventative shield.
III. Deliverables of Your Tailored Protocol
III. Direct Clinical Deliverables
*** If our standard options do not fully meet your needs, please contact us for a fully customized testing consultation tailored to your goals.
癌症 DNA 風險預測與超早期液體切片篩查 · 雙語功能醫學與分子腫瘤學臨床報告
檢測範疇 : 生殖細胞遺傳基因次世代定序 (NGS) 伴隨體細胞循環腫瘤 DNA (ctDNA) 液體切片篩查
臨床宗旨 : 結合「先天遺傳易感性風險（Hereditary Risk）」與「後天超早期癌變分子蹤跡（ctDNA Tracking）」，打破常規健檢影像學的空間極限，實現「未病預測、已病超早期發現」的雙重精準防線。
一、 為什麼要做這項檢測？
臨床核心：癌症的發生是先天基因缺陷與後天氧化壓力、慢性發炎、環境毒素交互作用的終點。傳統影像學檢 查（如低劑量電腦斷層 LDCT、超音波、大腸鏡）屬於「器質性診斷」，通常必須等到腫瘤長到 0.5 到 1 公分 以上（此時已包含數億個癌細胞）才能被看見。本檢測從分子基因維度出發，包含兩大核心防線：一是分析** 遺傳性基因缺陷**（如 BRCA 突變），了解一生中的相對患癌風險，引導生活方式避開雷區；二是利用超高靈 敏度的**液體切片技術（ctDNA）**，在人體器官尚未出現任何影像學可見結節前，直接捕捉癌細胞凋亡時釋 放入血的微量 DNA 片段，將癌症發現的時間點大幅提前數年。
1. 先天易感性評估：破解家族性遺傳癌症密碼： 約有 5% - 10% 的癌症具備顯著的家族遺傳傾向（如遺傳性乳癌卵巢癌症候群 HBOC、林奇症候群 Lynch Syndrome）。檢測先天生殖細胞（Germline）基因變異，能明確知曉自身是否攜帶癌變的「導火線」，這不是 為了製造恐懼，而是為了能精確進行針對性的日常防癌定製（例如強化肝臟 Phase I/II 代謝或排除特定重金 屬）。
2. 後天 ctDNA 液體切片：打破影像盲區，捕捉超早期癌變信號： 當人體內的突變細胞在免疫逃逸下悄悄增生並凋亡時，會將特異性的循環腫瘤 DNA (ctDNA) 釋放入血。液體切 片能夠以百萬分之一的超高靈敏度，在血液中撈取到這些帶有腫瘤特異性突變或甲基化修飾的分子。臨床研究 證實，ctDNA 能比常規 CT 影像提早多個月甚至數年釋出癌變警報。
3. 指導精準功能性介入與抗衰老營養處方： 基因決定了藍圖，但後天「表觀遺傳學 (Epigenetics)」決定了基因是否會被開啟。若檢出抑癌基因（如 p53） 功能低下或解毒基因（如 GSTM1）缺失，可以透過個人化每日定製餐包，高度加強十字花科植物精華（如 蘿 蔔硫素 Sulforaphane）、白藜蘆醇、高純度薑黃素或甲基化供體（活性葉酸），主動修復 DNA 損傷並強化細 胞抗發炎屏障。
二、 這項檢測具體能測到什麼?
本檢測結合了先天與後天兩大分子生物學維度，涵蓋多項跨癌種的高階基因標記分析：
1. 先天遺傳性癌症基因易感性篩檢 (Germline NGS Panel)
核心抑癌與 DNA 修復基因變異: 篩檢包含 BRCA1 / BRCA2（乳癌、卵巢癌、胰臟癌風險）、TP53（李佛美尼症候群）、PTEN、APC（家族性大腸瘜肉 症）等數十個核心基因。
錯配修復基因 (MMR Genes): MLH1, MSH2, MSH6, PMS2。評估是否有林奇症候群風險，這與大腸癌、 子宮內膜癌的遺傳易感性高度相關。
2. 後天循環腫瘤 DNA 體細胞突變篩檢 (ctDNA Somatic Mutation Liquid Biopsy)
高頻熱點驅動基因突變 (Driver Mutations): 利用超深 定序（Ultra-deep sequencing）捕捉血液游離 DNA 中的微量突變，包括 EGFR、KRAS、NRAS、 BRAF、PIK3CA 等。這能提示體內是否有處於亞臨床 狀態的腫瘤克隆細胞正在演化。
3. ctDNA 甲基化圖譜與癌症器官溯源 (Epigenetic ctDNA Methylation & Tissue-of-Origin)
表觀遺傳學甲基化特徵 (Methylation Signatures): 癌 細胞早期的 DNA 異常甲基化模式具有極高的特異 性。檢測能精確分析血液中 cfDNA 的表觀遺傳學指 紋。
組織器官定位 (Tissue of Origin, TOO): 一旦在血液 中發現超早期的微量癌變信號，演算法能根據甲基化 特徵直接追溯其源頭來自哪一個器官（如肺臟、肝 臟、結直腸、胃或胰臟），引導後續精準的醫學影像 跟蹤。
4. 系統性腫瘤免疫與表觀環境微標記 (Systemic Microenvironment & Onco-Immunological Balance)
微衛星不穩定性 (MSI 狀態): 透過 cfDNA 評估全身基 因組的穩定性。
發炎路徑與表觀遺傳負荷: 評估體內微環境是否具備 有利於癌症演化的「易發炎體質」，結合您的功能醫 學有機酸（OAT）與荷爾蒙（DUTCH）指標，全方位 搭建防癌防火牆。
三、 交付的個人化醫學管理應用
這項檢測的終極臨床價值，在於提供動態且客製化的「防癌終身管理路圖」：
【個人化每日營養包】
依據您細胞線粒體、抗氧化和脂肪酸的缺口,將每日所需的維生素 B 群、精準礦物質、CoQ10 與核心植物萃 取物,精準定量打包成每日獨立小包,告別大罐小罐、吞錯劑量的煩惱。
【專屬配方益生菌】
不使用大眾化通配菌株,而是根據您的腸道微生態指標、發炎耐受度與壞菌情況,挑選最能優化您腸道屏障與 菌腦軸的特異性活性菌株組合。
***若上述項目未能完全符合您的需求，歡迎聯絡我們，我們將為您安排專屬的客製化檢測諮詢。
*** 如果我們的標準選項無法完全滿足您的需求，請聯絡我們，我們將根據您的目標提供完全客製化的測試諮詢服務。